Paratek Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
PRTK Paratek Pharmaceuticals Inc
TATT TAT Technologies Ltd
DARE Dare Bioscience Inc
REXR-C Rexford Industrial Realty Inc
AQNA Algonquin Power & Utilities Corp
NAOV Nanovibronix Inc
IOT Samsara Inc
GSIT GSI Technology Inc
GME GameStop Corp
CMBM Cambium Networks Corp
Go

Health Care : Pharmaceuticals | Small Cap Growth

Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its commercial product, NUZYRA (omadacycline), is a once-daily oral and intravenous antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia (CABP), and acute skin and skin structure infections (ABSSSI) caused by susceptible pathogens. Its other commercial product SEYSARA (sarecycline), is a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The Sarecycline is a narrow spectrum tetracycline designed specifically for dermatological use. It markets omadacycline in the United States as an empiric monotherapy in the indications of ABSSSI and CABP for patients that have both a known or suspected resistant pathogen and at least one significant comorbidity.

Postmarket

Last Trade: Delayed
$1.92

Change Since Close Change Since Close Postmarket extended hours change is based on the last price at the end of the regular hours period. Premarket extended hours change is based on the day's regular session close.: 0.0017 (0.09%)

Bid: --

Ask: --

B/A Size: --

Market Hours

Closing Price: $1.92

Day's Change: 0.06 (3.23%)

Bid close: --

Ask close: --

B/A Size: --

Day's High: 1.94

Day's Low: 1.80

Volume (Above Average) Volume: 458,699 10-day average volume: 405,092: 458,699

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

The risk of loss in trading futures can be substantial. Clients must consider all relevant risk factors, including their own personal financial situation, before trading. Margin and level 2 options approval or higher is required. Not all account owners will qualify.

Dividends are converted to USD using the current rate of exchange at the end of the business day on the day the dividend went EX. Earnings are converted to USD using the current rate of exchange at the end of the business day on the day earnings were announced.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.

Postmarket

Change Since Close

Market Hours